coumarin
receiv
consider
attent
last
three
decad
lead
structur
discoveri
oral
bioavail
nonpeptid
antivir
agent
lot
structur
divers
coumarin
analogu
found
display
remark
array
affin
differ
molecular
target
antivir
agent
slight
modif
around
central
motif
result
pronounc
chang
antivir
spectrum
manuscript
thoroughli
review
design
discoveri
structureeact
relationship
studi
coumarin
analogu
antivir
agent
focus
mainli
lead
optim
develop
clinic
candid
virus
caus
agent
sever
epidem
fatal
diseas
human
immunodefici
viru
hiv
hepat
b
c
virus
hbv
hcv
respect
coronavirus
middl
east
respiratori
syndrom
mer
sever
acut
respiratori
syndrom
sar
influenza
season
pandem
smallpox
viral
haemorrhag
fever
ebola
dengu
chikungunya
etc
diseas
caus
global
societ
econom
impact
relat
unexpect
ill
death
well
troubl
daytoday
normal
life
activ
recent
emerg
newer
pandem
eg
influenza
ebola
zika
viru
etc
also
major
threat
public
health
emerg
virus
less
rna
genom
result
capabl
rapid
mutat
resist
clinic
avail
antivir
drug
thu
threat
resist
pose
major
challeng
clinic
manag
viral
infect
howev
field
antivir
drug
discoveri
wit
steadi
flow
excit
develop
sinc
advent
nucleosid
analogu
acyclovir
subsequ
antivir
drug
divers
chemic
class
approv
fda
mainli
manag
hiv
herp
hepat
b
c
influenza
b
virus
still
mani
molecul
variou
stage
clinic
trial
despit
progress
develop
antivir
agent
recent
year
still
press
need
newer
drug
act
differ
mechan
combat
problem
viral
resist
virus
constantli
evolv
develop
new
way
evad
drug
moreov
render
search
antivir
therapi
indistinct
sinc
difficult
identifi
uniqu
biochem
featur
virus
may
appropri
select
attack
without
harm
host
cell
coumarin
benzoapyron
consid
privileg
structur
design
novel
agent
high
affin
specif
differ
molecular
target
antivir
agent
coumarin
endow
uniqu
characterist
pharmacophor
planar
aromat
nucleu
connect
hydrogen
bond
acceptor
lacton
group
facilit
proteinligand
bind
coumarin
gain
moment
attent
last
three
decad
lead
structur
discoveri
oral
bioavail
nonpeptid
antivir
agent
sever
natur
semisynthet
synthet
lead
molecul
bear
coumarin
scaffold
previous
less
clinic
avail
hiv
proteas
inhibitor
pepetidomimet
although
peptidebas
inhibitor
got
edg
inhibitor
high
bind
affin
gener
lack
bioavail
requir
essenti
cellular
oral
activ
metabol
instabl
led
search
inhibitor
contain
nonpeptid
templat
might
offer
superior
biopharmaceut
properti
nonpeptid
hiv
proteas
inhibitor
receiv
consider
attent
owe
low
molecular
weight
high
oral
bioavail
low
clearanc
importantli
alreadi
use
therapeut
agent
human
warfarin
analogu
clinic
avail
drug
use
prevent
thrombosi
thromboembol
act
inhibit
vitamin
kdepend
convers
prothrombin
activ
form
thrombin
serin
proteas
enzym
catalys
mani
coagulationrel
reaction
moreov
sever
studi
demonstr
proteas
also
essenti
viral
enzym
attract
target
antihiv
drug
prompt
correl
bourinbaiar
colleagu
pioneer
studi
test
effect
oral
anticoagul
warfarin
viral
replic
spread
remark
found
low
dose
warfarin
effect
inhibit
hiv
infect
discoveri
lead
compound
promis
antiproteas
activ
pave
way
develop
new
class
nonpeptid
oral
antivir
agent
pursuit
goal
upjohn
laboratori
scientist
thaisrivong
et
al
evalu
similar
coumarin
deriv
potenti
hivproteas
inhibitor
use
fluoresc
base
highthroughput
screen
surprisingli
anoth
coumarin
base
anticoagul
phenprocoumon
emerg
novel
lead
templat
possess
weak
hiv
proteas
inhibitori
activ
k
mm
antivir
ed
mm
superior
pharmacokinet
fig
protein
crystallographi
complex
proteas
success
carri
order
get
clear
insight
interact
lead
optim
crystal
structur
reveal
scaffold
bind
mode
similar
peptid
inhibitor
catalyt
site
hydroxyl
form
two
hydrogenbond
aspart
residu
lacton
group
form
two
hydrogen
bond
isoleucin
residu
fig
studi
led
postul
essenti
pharmacophor
element
form
basi
ensu
structur
base
drug
design
activ
analogu
structurebas
drug
discoveri
sbdd
becom
essenti
tool
assist
fast
costeffici
lead
discoveri
optim
aim
understand
molecular
basi
diseas
util
knowledg
structur
biolog
target
process
use
sbdd
approach
xray
crstallographi
templat
optimis
develop
first
clinic
candid
deriv
nonpeptid
hiv
proteas
inhibitor
enter
phase
clinic
trial
fig
compound
show
excel
proteas
inhibit
k
nm
signific
antivir
activ
ic
mm
improv
pharmacokinet
properti
thu
consid
potenti
therapeut
agent
treatment
hiv
infect
molecular
hybrid
differ
pharmacophor
subunit
import
tool
lead
optim
provid
discoveri
numer
ligand
synergist
properti
base
approach
thaisrivong
cowork
upjohn
lab
extens
research
examin
crystal
structur
analogu
bound
hiv
proteas
superimpos
along
previous
report
peptidebas
inhibitor
rel
posit
peptid
nonpeptid
compound
hivproteas
reveal
addit
amid
chain
meta
posit
phenyl
ring
could
improv
bind
affin
coumarinbas
inhibitor
design
strategi
result
excit
seri
sever
promis
amino
acid
nonamino
acid
residu
contain
improv
enzymebind
affin
studi
reveal
addit
essenti
pharmacophor
incorpor
side
chain
posit
also
suitabl
accommod
subsit
enzym
activ
site
thu
previous
report
compound
also
provid
basi
possibl
modif
seri
potent
analogu
consequ
pyron
compound
contain
lhistidyl
amino
acid
residu
found
potent
analogu
seri
k
nm
resolut
four
specif
diastereom
signific
impact
enzymebind
affin
clearli
indic
insignific
stereochem
prefer
cell
cultur
assay
prove
compound
nontox
td
mm
antivir
potenc
ic
valu
mm
compar
previous
report
inhibitor
fig
replac
ethyl
group
cyclopropyl
group
posit
also
result
compound
improv
efficaci
gener
sar
seri
illustr
fig
romin
et
al
upjohn
laboratori
demonstr
uniqu
strategi
enhanc
secondari
bind
inhibitor
proteas
enzym
instead
pursu
explor
altern
strategi
increas
flexibl
replac
benzen
ring
satur
cycloalkyl
ring
ie
cyclopentylpyranon
cyclooctylpyranon
fig
result
surpris
cyclopropyl
contain
cyclooctylpyranon
emerg
potenti
proteas
enzym
inhibitor
good
pharmacokinet
rel
low
activ
cell
cultur
ic
mm
size
variat
cycloalkyl
ring
also
provid
interest
inform
bind
mode
conformationallyflex
cyclooctyl
ring
inhibitor
also
design
meta
substitut
carboxamid
deriv
significantli
activ
correspond
unsubstitut
cyclooctylpyranon
due
addit
hydrogen
bond
amid
group
substitut
cyclooctylpyranon
wide
varieti
arenesulfonamid
led
analogu
markedli
enhanc
antivir
resolut
via
chiral
hplc
yield
potent
enantiom
k
nm
antivir
ic
mm
oral
bioavail
compound
rang
rat
dog
h
satur
bond
pyron
ring
led
identif
cycloalkyldihydropyron
deriv
superb
bind
affin
hiv
proteas
k
valu
nm
excel
antivir
activ
cell
cultur
significantli
less
ed
valu
mm
unfortun
previou
agent
fail
earli
pharmacia
upjohn
pfizer
success
gener
buzz
june
report
promis
result
new
compound
tipranavir
potent
oral
bioavail
proteas
analogu
sulfonamid
class
k
pm
effect
highli
resist
strain
later
year
boehring
ingelheim
bi
acquir
exclus
right
tipranavir
aptivu
subsequ
approv
us
fda
group
scientist
tummino
et
al
also
parallel
research
develop
nonpeptid
inhibitor
screen
parkedavi
compound
librari
use
high
throughput
assay
identifi
phenoxypropyl
deriv
phenylthio
deriv
revers
competit
inhibitor
effect
micro
molar
level
two
deriv
excel
lead
molecul
develop
therapeut
effect
proteas
inhibitor
sinc
small
achir
nonpeptid
molecul
easili
synthes
possess
promis
pharmacolog
properti
bind
mode
compound
studi
employ
mont
carlobas
dock
procedur
xray
crystal
analysi
subsequ
sever
analogu
prepar
test
bind
interact
improv
overal
bind
affin
amongst
butyl
emerg
activ
compound
ic
mm
optim
pyron
deriv
yield
sever
potent
analogu
sever
fold
higher
bind
affin
among
ec
nm
select
preclin
evalu
unfortun
clinic
progress
compound
report
probabl
consequ
merg
compani
pfizer
parkedavi
laboratori
also
identifi
dimethyl
deriv
warfarin
ninefold
potent
parent
compound
ic
valu
later
pursu
warfarin
analogu
fig
collabor
endeavour
databas
search
wang
group
laboratori
medicin
chemistri
frederick
cancer
research
develop
centr
nation
cancer
institut
nciu
result
group
eight
promis
nonpeptid
proteas
inhibitor
along
class
compound
fig
pharmacophor
queri
use
search
deriv
directli
xray
crystallographi
structur
proteaseinhibitor
complex
result
invitro
hiv
proteas
bioassay
evalu
clearli
suggest
compound
contain
singl
moieti
capabl
bind
proteas
compound
nsc
id
mm
id
mm
ic
mm
contain
dimer
tetram
may
superior
lead
develop
compound
nsc
also
found
inhibitor
integras
revers
transcriptas
rt
compound
therefor
repres
multitarget
lead
develop
potenti
antiaid
drug
base
structur
studi
also
propos
pharmacophor
essenti
hiv
proteas
activ
optim
lead
molecul
nsc
structur
simpler
coumarin
deriv
fragment
tetram
reveal
coumarin
dimer
contain
arylmethylen
essenti
hiv
integras
pharmacophor
inde
turn
modif
central
phenyl
ring
lipophil
extend
aromat
system
addit
substitu
coumarin
ring
significantli
enhanc
potenc
consid
conspicu
signific
deriv
proteas
inhibitor
kirkiacharian
cowork
synthes
set
object
investig
influenc
modif
coumarin
result
demonstr
hydroxyl
group
nearer
group
interfer
hydrogen
bond
group
proteas
howev
distant
deriv
activ
antihiv
agent
replac
benzyl
group
indic
flexibl
lead
signific
chang
activ
similarli
anoth
scientist
stanchev
et
al
also
report
deriv
proteas
inhibitor
compound
test
proteas
activ
cell
infect
highest
inhibit
pr
highest
cell
surviv
demonstr
compound
contain
mnitrophenyl
deriv
fig
effort
identifi
novel
antihiv
agent
natur
sourc
huang
et
al
report
new
class
tricycl
coumarin
anti
hiv
suksdofin
r
isovaleryloxi
dihydroseselin
pyranocoumarin
deriv
two
cisori
acyl
group
posit
obtain
plant
lomatium
suksdorfii
umbellifera
antihiv
agent
structur
suksdorin
relat
coumarin
deriv
pteryxin
previous
establish
willetti
et
al
suksdorfin
found
inhibit
replic
lymphocyt
vitro
ec
valu
mm
therapeut
index
valu
observ
vari
acyl
group
posit
pyran
ring
greatli
affect
antihiv
potenc
unsubstitut
analogu
seselin
led
discoveri
first
show
extrem
potent
inhibitori
activ
ec
mm
replic
cell
line
remark
therapeut
index
ti
howev
diastereoisom
time
less
activ
enthus
promis
earli
find
lee
et
al
report
numer
dck
analogu
thorough
structureact
relationship
sar
demonstr
r
configur
planar
coumarin
ring
system
essenti
structur
featur
antihiv
activ
alkyloalkyl
substitu
coumarin
favour
enhanc
antihiv
activ
decreas
toxic
dck
howev
develop
dckanalogu
effect
antiaid
drug
hinder
problem
low
water
solubl
henc
less
bioavail
ineffect
multidrug
resist
hiv
strain
rtmdr
therefor
further
develop
dckrelat
clinic
drug
candid
identifi
hydroxymethyl
deriv
dck
first
moder
oral
bioavail
drug
water
solubl
f
act
inhibit
product
doublestrand
viral
dna
singlestrand
dna
intermedi
moreov
ring
open
dck
analogu
secodck
contain
lesser
hydrogen
bond
acceptor
also
show
improv
adm
properti
found
effect
rtmdr
strain
isomer
replac
coumarin
chromon
result
dcp
analogu
potent
antihiv
agent
resist
strain
rtmdr
secodcp
extend
conjug
xanthenon
analogu
also
turn
promis
untreat
resist
strain
fig
discoveri
develop
antihiv
compound
calanolid
analogu
interest
account
lead
identif
brought
promis
drug
candid
patient
hiv
address
challeng
issu
drug
resist
kashman
cowork
nci
laboratori
discov
new
class
coumarin
deriv
known
calanolid
tropic
rainforest
tree
calophyllum
lanigerum
antihiv
chemotyp
calanolid
b
c
chemic
tetracycl
dipyranocoumarin
three
chiral
carbon
centr
scaffold
posit
studi
purifi
bacteri
recombin
revers
transcriptas
rt
reveal
calanolid
specif
rt
inhibitor
activ
aztresist
pyridinoneresist
strain
reduct
activ
observ
analogu
contain
one
lesser
chiral
centr
thu
calanolid
repres
substanti
departur
known
class
therefor
provid
novel
new
antihiv
chemotyp
drug
develop
limit
avail
natur
resourc
total
synthesi
racem
resolut
calanolid
carri
bioassay
calanolid
account
antihiv
activ
howev
isom
inact
relat
novel
rt
inhibitor
inophyllum
b
c
e
p
isol
fraction
calophyllum
inophyllum
linn
malaysian
indigen
cordatolid
b
isol
calophyllum
cordatooblongum
srilankan
indigen
prompt
result
number
close
relat
pyranocoumarin
report
afterward
differ
calophyllum
speci
semisynthet
deriv
also
design
potent
antihiv
agent
current
calanolid
sponsor
sarawak
medichem
pharmaceut
complet
phase
iii
clinic
trial
combin
therapi
hiv
fig
oral
toxic
drug
minim
report
advers
effect
dizzi
nausea
oili
aftertast
search
natur
antiaid
agent
furanocoumarin
isol
differ
plant
viz
ferula
sumbul
prango
tschimganica
fig
among
furanocoumarin
imperatronin
emerg
promis
antihiv
agent
imperatronin
inhibit
hiv
replic
lymphocyt
ec
valu
mgml
inhibit
uninfect
cell
growth
ic
valu
mgml
calcul
therapeut
index
ti
valu
studi
mechan
action
reveal
unlik
coumarin
imperatronin
inhibit
revers
transcript
integras
inhibit
gene
express
therebi
arrest
cell
g
phase
cell
cycl
result
highlight
potenti
transcript
factor
target
natur
antihiv
compound
furancoumarin
might
potenti
therapeut
role
manag
aid
japanes
research
group
led
uchiumi
et
al
demonstr
natur
occur
compound
gener
present
tea
leav
suppress
tpainduc
hiv
promot
activ
compound
show
suppress
effect
cytomegaloviru
cmv
promot
suggest
act
specif
hiv
promot
result
suggest
deriv
might
potenti
candid
develop
novel
antihiv
drug
target
hiv
promot
activ
encourag
observ
olmedo
et
al
synthes
differ
deriv
evalu
antihiv
activ
sulfanylphenylcoumarin
deriv
emerg
potent
inhibitor
hiv
replic
act
dual
inhibit
nfkb
unspecif
tat
function
wherea
deriv
umbelliferon
deriv
act
specif
tat
inhibitori
activ
synthet
coumarin
potent
mesuol
nfkb
tat
molecular
target
less
effect
rv
assay
thu
presenc
prenyl
prenacyl
substitu
attach
coumarin
nucleu
could
prerequisit
structur
factor
reinforc
antivir
activ
fig
fig
detail
sar
minim
pharmacophor
respons
vpr
inhibitori
activ
also
explor
bind
assay
vpr
mutant
reveal
hydrophob
region
residu
potenti
involv
bind
inhibitor
therefor
studi
provid
new
insight
molecular
mechan
vprinhibitor
could
pragmat
futur
drug
develop
marquez
et
al
report
two
natur
mesuol
isomesuol
obtain
tree
marila
pluricostata
effect
antihiv
agent
act
novel
mechan
tnfamedi
transcript
activ
coumarin
devoid
revers
transcript
intregr
activ
like
coumarin
isom
suppress
replic
jurkat
cell
ic
rang
mm
complet
inhibit
mm
howev
mesuol
exhibit
potent
antihiv
activ
peripher
blood
mononuclear
cell
acut
infect
clone
thu
act
novel
mechan
could
potenti
lead
develop
potent
therapeut
agent
manag
aid
drugresist
hiv
strain
later
scientist
laboratori
report
two
compound
class
potent
hiv
transcript
inhibitor
act
mainli
interfer
nfkb
tat
function
fig
likewis
sever
studi
also
prove
consid
promis
model
compound
develop
novel
inhibitor
import
pharmacophor
antivir
activ
depict
mani
studi
therefor
abd
elhafez
et
al
report
seri
thiazolidinon
oxadiazolin
hydrazon
contain
coumarin
deriv
antivir
agent
among
compound
pchlorophenylthiazolidinon
deriv
highest
activ
abl
reduc
number
plaqu
concentr
mgml
mic
cytotox
cd
valu
mgml
bhavsar
et
al
also
design
novel
antihiv
agent
molecular
hybrid
acid
substitut
benzothiazol
compound
show
moder
potent
activ
wildtyp
ec
rang
mgml
sar
demonstr
substitut
coumarin
nucleu
hydroxyl
group
increas
activ
wherea
bulki
group
decreas
antihiv
properti
potent
compound
seri
acetamid
ec
mg
ml
see
fig
new
class
marin
compound
potenti
develop
clinic
use
integras
inhibitor
obtain
didemnid
ascidian
chemic
group
dopa
propion
acid
deriv
pyrrol
alkaloid
contain
coumarin
nucleu
commonli
known
lamellarin
compound
effect
integras
protein
attract
target
antiretrovir
chemotherapi
especi
member
famili
lamellarin
found
inhibit
integras
protein
vitro
viral
replic
cultur
cell
site
action
integras
protein
also
map
test
activ
delet
mutant
integras
aesculetin
esculetin
cichorigenin
dihydroxi
deriv
coumarin
obtain
aerial
part
artemisia
capillari
also
report
antihiv
agent
inhibit
hiv
replic
lymphocyt
cell
ed
valu
mgml
therapeut
index
fig
viral
hepat
potenti
seriou
infecti
diseas
mainli
affect
liver
caus
hepatocellular
carcinoma
major
caus
morbid
mortal
worldwid
therefor
recent
research
effort
focus
develop
antivir
therapi
vaccin
strategi
virus
sever
coumarin
analogu
also
prove
substanti
antihepat
viru
activ
recent
new
compound
librari
hybrid
coumarinbenzimidazol
deriv
connect
inhibit
hcv
rna
replic
effect
cell
prolifer
data
new
compound
librari
provid
clue
develop
sever
coumarinbenzimidazol
relat
conjug
antihcv
agent
subsequ
modif
benzimidazol
nucleu
heterobicycl
imidazopyridin
purin
benzoxazol
benzothiazol
also
carri
establish
structureact
relationship
sar
basi
new
compound
librari
promis
compound
imidazopyridinecoumarin
purinecoumarin
benzoxazolecoumarin
inhibit
hcv
replic
ec
mm
respect
howev
benzothiazolylcoumarin
analogu
least
effect
hcv
encourag
result
purinecoumarin
conjug
pave
way
develop
correspond
ribonucleosidecoumarin
analogu
seven
among
new
compound
found
inhibit
hcv
subgenom
replicon
replic
huh
cell
line
amongst
purin
analogu
yl
yl
purin
show
potent
activ
ec
valu
mm
anoth
seri
benzimidazol
ring
replac
imidazol
ring
explor
sar
imidazoleecoumarin
conjug
observ
unsubstitut
imidazol
ie
hydrogen
atom
posit
cl
f
br
ome
substitut
coumarin
nucleu
result
compound
signific
activ
remov
methylenethio
linker
benzimidazol
coumarin
afford
directli
hing
coumarinbenzimidazol
deriv
potent
antihcv
agent
dimethylimidazolecoumarin
methylimidazolebenzocoumarin
exhibit
promis
ec
valu
low
mm
respect
incorpor
dribofuranos
afford
correspond
nucleosid
slight
abat
activ
thu
detail
studi
underlin
signific
potenti
coumarinbenzimidazol
conjug
lead
compound
develop
novel
therapeut
agent
treatment
hcv
fig
recent
manvar
et
al
synthes
imidazo
fig
potenti
inhibitor
abil
titl
compound
interact
protein
investig
silico
screen
nonstructur
viral
protein
hybrid
coumarin
deriv
interact
alloster
site
protein
exhibit
dock
confirm
good
conform
refer
ligand
use
methylcoumarin
pharmacophor
peng
cowork
design
novel
anilinocoumarin
deriv
agent
hcv
observ
substitu
bear
strong
electrondon
motif
phenyl
ring
crucial
antihcv
activ
trimethoxyanilino
deriv
emerg
potent
antivir
agent
ec
valu
mm
si
compound
found
act
novel
molecular
mechan
induct
interferona
ifn
mediat
antivir
respons
thu
anilinocoumarin
deriv
could
lead
compound
antihcv
therapi
circumv
drug
resist
due
hcv
viru
mutat
fig
seri
mannich
base
osthol
analogu
synthes
evalu
antiflavivirida
particular
antihcv
mazzei
et
al
interest
pattern
sar
observ
among
differ
virus
deriv
found
activ
bovin
viral
diarrhoea
viru
bvdv
deriv
activ
respiratori
syncyti
viru
rsv
wherea
deriv
ineffect
flavivirida
group
viru
molecular
dock
studi
reveal
dna
polymeras
potenti
involv
inhibit
hcv
unsymmetr
methylen
deriv
name
coumarin
bridg
chromon
indol
also
report
moder
activ
antivir
agent
anoth
natur
compound
collinin
geranyloxycoumarin
isol
root
bark
basu
et
al
identifi
character
coumestan
isoflavonoid
class
phytoestrogen
novel
class
agent
hepat
c
viru
hcv
essenti
viral
rna
replic
therefor
key
target
hcv
inhibitor
natur
occur
coumestan
wedelolacton
exhibit
rnadepend
rna
polymeras
rdrp
inhibit
micromolar
rang
prompt
synthesis
anoth
four
differ
synthet
analogu
found
effect
inhibitor
ic
valu
mm
fold
activ
conclud
efficaci
coumestan
invers
correl
hydrophob
molecular
dock
studi
reveal
modif
benzofuran
coumarin
core
along
peripher
hydroxyl
methoxi
group
valuabl
afford
compound
might
ideal
inhibitor
accommod
bind
pocket
fig
angular
furanocoumarin
angelicin
found
safer
pharmacophor
element
antiinfluneza
activ
howev
linear
analogu
psoralen
highli
phototox
isom
due
abil
crosslink
deoxyribonucl
acid
dna
novel
angelicin
deriv
potent
influenza
viru
inhibitor
identifi
use
cellbas
highthroughput
screen
around
twenti
thousand
compound
structur
novelti
hit
molecul
encourag
pursu
leadoptim
class
sar
explor
thiophenoyl
substitut
angellicin
emerg
optimis
lead
exhibit
enhanc
activ
compar
hit
compound
found
broad
spectrum
antiinfluenz
agent
effect
influenza
influenza
b
strain
drug
zanamivir
plasmidbas
revers
genet
use
luciferas
assay
yield
key
insight
molecular
mechan
angellicin
deriv
point
toward
viral
ribonucleoprotein
rnp
probabl
molecular
target
agent
later
benzoyl
substitut
angelicin
also
emerg
novel
inhibitor
influenza
viru
exhibit
excel
antivir
efficaci
oseltamivirresist
viru
ec
mm
also
exhibit
broad
antivir
spectrum
variou
strain
influenza
influenza
b
virus
compound
act
target
viral
rnp
respons
viral
rna
synthesi
molecul
later
establish
effect
antihiv
agent
inhibit
tatmedi
transcript
akt
pathway
ec
nm
thu
molecul
potenti
becom
promis
lead
compound
develop
novel
therapeut
agent
effect
influenza
infect
fig
year
mani
natur
plant
base
compound
report
potenti
antivir
agent
effect
herp
simplex
virus
fig
year
ishikawa
et
al
isol
uniqu
coumarinnaphthoquinon
dimer
call
toddacoumaquinon
toddalia
asiatica
rutacea
evalu
antivir
activ
herp
simplex
viru
type
herp
simplex
viru
type
human
immunodefici
viru
type
compound
found
weakli
activ
hsv
ec
mgml
ineffect
hiv
xu
colleagu
also
demonstr
inhibit
human
herpesviru
replic
could
achiev
use
rutamarin
natur
furanocoumarin
obtain
plant
ruta
graveolen
l
common
rue
studi
total
compound
virtual
screen
topoisomeras
ii
inhibit
properti
subsequ
test
antivir
activ
natur
product
rutamarin
exhibit
signific
inhibit
viral
dna
synthesi
virion
caus
kaposi
sarcoma
ks
aidsassoci
malign
thu
rutamarin
could
potent
clinic
candid
treatment
human
diseas
associ
kshv
infect
sesquiterpen
coumarin
kellerin
isol
gum
resin
ferula
asafoetida
significantli
reduc
viral
titr
herp
viru
type
dna
viral
strain
ko
concentr
mgml
inhibit
rate
respect
kellerin
effect
ec
mgml
compound
deriv
also
studi
antivir
agent
result
somewhat
encourag
might
due
nonconform
pharmacophor
way
back
giannella
et
al
report
deriv
show
good
antivir
activ
howev
compound
develop
high
degre
cytotox
order
lower
toxic
activ
molecul
modifi
preserv
cyclic
adicarbonyl
structur
prepar
sever
mannich
base
preliminari
examin
compound
show
appreci
antivir
activ
fig
howev
deriv
bi
found
exert
inhibitori
activ
ko
g
vaccinia
viru
tkko
acvr
rang
mm
continu
studi
hybrid
coumarinbenzimidazol
appeal
antihcv
activ
hwu
et
al
investig
number
new
hybrid
compound
uracilecoumarinearen
potenti
inhibit
agent
chikungunya
viru
chikv
fig
set
doubli
uracilecoumarin
tripli
conjug
uracilecoumarinearen
evalu
establish
sar
extens
doubli
conjug
uracilecoumarin
tripli
conjug
uracilecoumarinearen
use
linker
vital
antichikv
activ
bezouracil
deriv
better
select
index
compar
uracil
thymin
pohjala
et
al
screen
around
natur
compound
clinic
approv
drug
chikungunya
viru
chikv
replicon
cell
line
semliki
forest
viru
sfv
alpha
viru
format
one
coumarin
antisfv
screen
hit
exhibit
thenoyl
deriv
also
effect
chikv
fig
present
review
aim
provid
import
insight
design
newer
coumarin
base
antivir
agent
sinc
signific
research
devot
develop
antivir
coumarin
divers
class
natur
semisynthet
synthet
coumarin
analogu
report
promis
antivir
agent
effect
broad
spectrum
virus
among
natur
coumarin
remain
fascin
rich
sourc
lead
compound
boast
ingeni
function
motif
proven
import
precursor
mani
effect
antivir
drug
sever
class
coumarin
abandon
improv
term
efficaci
select
target
achiev
optim
pharmacokinet
pharmacodynam
properti
given
promis
result
potenti
antivir
activ
coumarin
could
use
futur
clinic
moreov
review
sure
provid
new
horizon
research
antivir
agent
give
better
understand
role
molecul
diseas
therapeut
agent
could
effect
author
confirm
articl
content
conflict
interest
